What it is
Regulatory status: medication in several countries (prescription choline alphoscerate) and supplement in the United States
At a glance
What it is, why people use it, the evidence, and what to know before trying it.
Why people use it
- Cognition in mild-to-moderate Alzheimer’s disease and mixed/vascular dementia (the Italian / Mexican pharmaceutical claim at ~1,200 mg/day).
- Cognitive recovery after acute stroke or TIA.
- Delayed conversion from mild cognitive impairment to dementia (the 2025 Korean observational claim).
- Power and force in resistance or jump tasks (the sports-nutrition claim).
- Acute growth-hormone rise (sold as if it were hypertrophy or fat-loss).
- Acute cognition / “focus” in healthy adults at pre-workout doses (~300–600 mg).
Evidence at a glance
The only human outcome literature that is large enough to take seriously is **pharmaceutical choline alphoscerate at about 1,200 mg/day for months** in older adults with Alzheimer’s or vascular cognitive impairment: a 2003 Mexican placebo-controlled RCT (ADAS-Cog about 6 points better than placebo at 180 days), Italian add-on work with donepezil (ASCOMALVA), and a 2023 meta-analysis that is real but fragile (monotherapy MMSE I² = 98%). That is **moderate** evidence for a **small-to-moderate cognitive effect in diagnosed dementia at the drug dose**, not a cure, and not independently reproduced in a modern large Western outcomes RCT.